Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 2115-2119, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (26)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saedi, M. S.
Right arrow Articles by Rittenhouse, H. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saedi, M. S.
Right arrow Articles by Rittenhouse, H. G.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1998;44:2115-2119.)
© 1998 American Association for Clinical Chemistry, Inc.

Enzymes and Protein Markers

The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia

Mohammad S. Saedia, Timothy M. Hill, Kristine Kuus-Reichel, Abhay Kumar, Janice Payne, Stephen D. Mikolajczyk, Robert L. Wolfert, and Harry G. Rittenhouse

a Address correspondence to this author at: Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc., P.O. Box 269006, San Diego, CA 92196. Fax 619-621-4610; e-mail mssaedi{at}beckman.com.

Prostate-specific antigen (PSA, hK3) is a diagnostic marker for prostatic cancer but lacks the specificity to sufficiently distinguish between prostatic cancer and benign prostatic hyperplasia (BPH). Human glandular kallikrein 2 (hK2) has been proposed as a potential diagnostic marker for prostate cancer that could complement the current PSA test. Recently we demonstrated that proPSA is present in prostate cancer sera. This study examines the expression of prohK2 in prostate cells and its presence in human sera. Western blot analysis was used to assess prohK2 expression in the human carcinoma cell line, LNCaP. A highly specific and sensitive dual monoclonal immunoassay for prohK2 was developed and used to assess the presence of prohK2 in human sera. prohK2 was detected in the spent media of LNCaP cells. Furthermore, prohK2 was present at immunodetectable concentrations in human sera, and its concentration was increased in prostatic cancer and BPH. These results indicate for the first time that prohK2 is secreted by human prostate cells and is a major component of uncomplexed (free) hK2 in human sera. In addition, prohK2 in human sera is associated with prostate disease and thus may be a useful marker for prostatic cancer and BPH.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
V. Vaisanen, S. Eriksson, K. K. Ivaska, H. Lilja, M. Nurmi, and K. Pettersson
Development of Sensitive Immunoassays for Free and Total Human Glandular Kallikrein 2
Clin. Chem., September 1, 2004; 50(9): 1607 - 1617.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Haese, V. Vaisanen, J. A. Finlay, K. Pettersson, H. G. Rittenhouse, A. W. Partin, D. J. Bruzek, L. J. Sokoll, H. Lilja, and D. W. Chan
Standardization of Two Immunoassays for Human Glandular Kallikrein 2
Clin. Chem., April 1, 2003; 49(4): 601 - 610.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
F. Kosari, Y. W. Asmann, J. C. Cheville, and G. Vasmatzis
Cysteine-rich Secretory Protein-3: A Potential Biomarker for Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1419 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. A. Finlay, J. R. Day, C. L. Evans, R. Carlson, K. Kuus-Reichel, L. S. Millar, S. D. Mikolajczyk, M. Goodmanson, G. G. Klee, and H. G. Rittenhouse
Development of a Dual Monoclonal Antibody Immunoassay for Total Human Kallikrein 2
Clin. Chem., July 1, 2001; 47(7): 1218 - 1224.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. Stephan, K. Jung, M. Lein, P. Sinha, D. Schnorr, and S. A. Loening
Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1133 - 1147.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
A. Magklara, A. Scorilas, W. J. Catalona, and E. P. Diamandis
The Combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA
Clin. Chem., November 1, 1999; 45(11): 1960 - 1966.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.